 |
27 Diseases |  |
22 Trials |
|
22 Trials |  |
341 News |  |
| «1234567» |
- | bupropion sustained-release / generics
Clinical, Journal: The Concise Health Risk Tracking Self-Report (CHRT-SR) assessment of suicidality in depressed outpatients: A psychometric evaluation. (Pubmed Central) - Sep 6, 2019
The CHRT-SR has good to excellent psychometric properties and is sensitive to change in suicidal thinking and propensity toward suicidal behavior in outpatients with major depressive disorder. It allows for the monitoring of thoughts and feelings associated with increased suicidal risk as well as levels of thoughts about suicide.
- | Chantix (varenicline) / Pfizer
Trial completion date, Trial primary completion date: Combining Varenicline and Bupropion for Smoking Cessation (clinicaltrials.gov) - Sep 3, 2019
P3, N=385, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
It allows for the monitoring of thoughts and feelings associated with increased suicidal risk as well as levels of thoughts about suicide. Trial completion date: May 2020 --> May 2021 | Trial primary completion date: May 2019 --> May 2020
- | bupropion sustained-release / generics, bupropion / generics
Journal: Comparative study of acupoint catgut embedding and bupropion hydrochloride sustained-release tablets for tobacco dependence (Pubmed Central) - Aug 22, 2019
Acupoint catgut embedding can effectively improve the symptoms of tobacco dependence after smoking cessation. Its curative effect is close to that of bupropion hydrochloride sustained-release tablets, and it has good clinical compliance and less adverse reactions.
- | bupropion sustained-release / Generic mfg.
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: Mobile Contingency Management for Concurrent Abstinence From Alcohol and Smoking (clinicaltrials.gov) - Aug 19, 2019
P=N/A, N=45, Active, not recruiting, Sponsor: Duke University
Its curative effect is close to that of bupropion hydrochloride sustained-release tablets, and it has good clinical compliance and less adverse reactions. Recruiting --> Active, not recruiting | N=10 --> 45 | Trial completion date: Feb 2021 --> Feb 2020 | Trial primary completion date: Nov 2020 --> Feb 2020
- | Chantix (varenicline) / Pfizer
Preclinical, Journal, HEOR: A behavioral economic analysis of the value-enhancing effects of nicotine and varenicline and the role of nicotinic acetylcholine receptors in male and female rats. (Pubmed Central) - Aug 3, 2019
Nicotine and varenicline enhanced VS demand equivalently between the sexes as evaluated by reinforcer demand. However, α4β2* receptor antagonism attenuated value enhancement by nicotine and varenicline in females, but only of nicotine in males.
- | bupropion sustained-release / Generic mfg.
Enrollment open: PARQuit Smoking Cessation Intervention for Adults With Serious Mental Illness (clinicaltrials.gov) - Aug 2, 2019
P4, N=60, Recruiting, Sponsor: University of California, San Francisco
However, α4β2* receptor antagonism attenuated value enhancement by nicotine and varenicline in females, but only of nicotine in males. Not yet recruiting --> Recruiting
- | methamphetamine / Generic mfg.
Trial completion, Enrollment change: Bupropion in the Treatment of Methamphetamine Dependence (clinicaltrials.gov) - Jul 25, 2019
P=N/A, N=40, Completed, Sponsor: University of Nebraska
Not yet recruiting --> Recruiting Recruiting --> Completed | N=60 --> 40
- | Chantix (varenicline) / Pfizer
Enrollment closed, Enrollment change: Treating Smokeless Tobacco Use in Rural Veterans (clinicaltrials.gov) - Jul 24, 2019
P=N/A, N=123, Active, not recruiting, Sponsor: Mark Vander Weg
Recruiting --> Completed | N=60 --> 40 Enrolling by invitation --> Active, not recruiting | N=50 --> 123
- | Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Evaluation of CYP450 Activities in Diabetic Patients vs. Non-diabetic Subjects (clinicaltrials.gov) - Jul 23, 2019
P4, N=73, Completed, Sponsor: Centre hospitalier de l'Universit
Enrolling by invitation --> Active, not recruiting | N=50 --> 123 Recruiting --> Completed | N=126 --> 73 | Trial completion date: Oct 2019 --> Jul 2019 | Trial primary completion date: Jan 2019 --> Jul 2019
- | bupropion sustained-release / Generic mfg.
Enrollment closed, Enrollment change: Smoking Cessation for People Living With HIV/AIDS (clinicaltrials.gov) - Jul 22, 2019
P=N/A, N=165, Active, not recruiting, Sponsor: Wayne State University
Recruiting --> Completed | N=126 --> 73 | Trial completion date: Oct 2019 --> Jul 2019 | Trial primary completion date: Jan 2019 --> Jul 2019 Recruiting --> Active, not recruiting | N=400 --> 165
- | bupropion sustained-release / Generic mfg.
Trial completion date, Trial primary completion date: Smoking Cessation for People Living With HIV/AIDS (clinicaltrials.gov) - Jul 11, 2019
P=N/A, N=400, Recruiting, Sponsor: Wayne State University
Recruiting --> Active, not recruiting | N=400 --> 165 Trial completion date: Dec 2019 --> Jul 2020 | Trial primary completion date: Dec 2019 --> Jul 2020
- ||| Auvelity (bupropion/dextromethorphan) / Axsome Therap
Trial completion: AXS-05 Phase II Trial on Smoking Behavior (clinicaltrials.gov) - Jun 12, 2019
P2, N=58, Completed, Sponsor: James Davis
Trial completion date: Dec 2019 --> Jul 2020 | Trial primary completion date: Dec 2019 --> Jul 2020 Active, not recruiting --> Completed
- | bupropion sustained-release / Generic mfg.
New P4 trial: CPT-SMART for Treatment of PTSD and Cigarette Smoking (clinicaltrials.gov) - Jun 6, 2019
P4, N=120, Not yet recruiting, Sponsor: VA Office of Research and Development
- | bupropion sustained-release / generics, carbamazepine / generics, allopurinol / generics
It's well documented for lamotrigine. Other culprits in the mix: allopurinol and zyban. This week I've seen carbamazepine induced leucopenia + febrile (Twitter) - May 28, 2019
- | bupropion sustained-release / Generic mfg.
New P4 trial: PARQuit Smoking Cessation Intervention for Adults With Serious Mental Illness (clinicaltrials.gov) - May 15, 2019
P4, N=60, Not yet recruiting, Sponsor: University of California, San Francisco
- ||| Chantix (varenicline) / Pfizer
Trial completion date: Combining Varenicline and Bupropion for Smoking Cessation (clinicaltrials.gov) - May 14, 2019
P3, N=385, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Trial completion date: May 2019 --> May 2020
- || Auvelity (bupropion/dextromethorphan) / Axsome Therap
Enrollment closed: AXS-05 Phase II Trial on Smoking Behavior (clinicaltrials.gov) - May 13, 2019
P2, N=60, Active, not recruiting, Sponsor: James Davis
Trial completion date: May 2019 --> May 2020 Recruiting --> Active, not recruiting
- | Chantix (varenicline) / Pfizer
Enrollment open: Individualizing Pharmacotherapy for African American Smokers (clinicaltrials.gov) - May 6, 2019
P3, N=392, Recruiting, Sponsor: University of Kansas Medical Center
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Chantix (varenicline) / Pfizer
Trial completion: Web-based Smoking Cessation Program for Tribal College Students (clinicaltrials.gov) - Apr 20, 2019
P3, N=251, Completed, Sponsor: Won Choi, PhD, MPH
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Chantix (varenicline) / Pfizer
Enrollment closed, Enrollment change: Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy (clinicaltrials.gov) - Apr 16, 2019
P1, N=9, Active, not recruiting, Sponsor: Wake Forest University Health Sciences
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=60 --> 9
- | bupropion sustained-release / Generic mfg.
Trial completion: Mobile Health Technology to Enhance Abstinence in Smokers With Schizophrenia (clinicaltrials.gov) - Apr 5, 2019
P4, N=35, Completed, Sponsor: Duke University
Recruiting --> Active, not recruiting | N=60 --> 9 Active, not recruiting --> Completed
- | Chantix (varenicline) / Pfizer
New P3 trial: Individualizing Pharmacotherapy for African American Smokers (clinicaltrials.gov) - Apr 1, 2019
P3, N=392, Not yet recruiting, Sponsor: University of Kansas Medical Center
- || bupropion sustained-release / generics
More #MedicalLaboratory & others 2follow: @kmbernhardt @bactiman63 @MLSatLoyola @TXST_CLS @CLSeditor @CLSI_LabNews @jimflanigancae @krajbj @brendabarnes @IDstewardship @jazzybandb @JATetro @JMiranda_22 @byancanarro @MeghanColvin @CarlosdelRio7 @owenmp @FromTheLabBench @aetiology (Twitter) - Mar 25, 2019
- | bupropion sustained-release / Generic mfg.
Trial initiation date: Smoking Cessation Interventions for People Living With HIV in Nairobi, Kenya (clinicaltrials.gov) - Mar 6, 2019
P3, N=300, Not yet recruiting, Sponsor: University of Maryland
Active, not recruiting --> Completed Initiation date: Jan 2019 --> Aug 2019
- || Auvelity (bupropion/dextromethorphan) / Axsome Therap
Trial completion date, Trial primary completion date: AXS-05 Phase II Trial on Smoking Behavior (clinicaltrials.gov) - Jan 14, 2019
P2, N=60, Recruiting, Sponsor: James Davis
Initiation date: Jan 2019 --> Aug 2019 Trial completion date: Jan 2019 --> May 2019 | Trial primary completion date: Dec 2018 --> Mar 2019
- | Chantix (varenicline) / Pfizer
Trial primary completion date: Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy (clinicaltrials.gov) - Dec 28, 2018
P1, N=60, Recruiting, Sponsor: Wake Forest University Health Sciences
Trial completion date: Jan 2019 --> May 2019 | Trial primary completion date: Dec 2018 --> Mar 2019 Trial primary completion date: Jan 2019 --> Jul 2019
- | Chantix (varenicline) / Pfizer
Journal: Pharmacological intervention and abstinence in smokers undergoing cessation treatment: A psychophysiological study. (Pubmed Central) - Dec 24, 2018
Independent of medication treatment, lower baseline NER, as measured by the corrugator EMG activity, predicted a higher likelihood of smoking abstinence 1 and 3months after quitting smoking. These findings indicate the important roles of varenicline in negative affect processing and negative emotional reactivity in the course of smoking cessation.
- | Chantix (varenicline) / Pfizer
Enrollment closed, Trial primary completion date: Web-based Smoking Cessation Program for Tribal College Students (clinicaltrials.gov) - Oct 13, 2018
P3, N=300, Active, not recruiting, Sponsor: Won Choi, PhD, MPH
These findings indicate the important roles of varenicline in negative affect processing and negative emotional reactivity in the course of smoking cessation. Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2018 --> Mar 2019
- | bupropion sustained-release / Generic mfg.
Trial completion: Abstinence Reinforcement Therapy (ART) for Homeless Veteran Smokers (clinicaltrials.gov) - Oct 12, 2018
P4, N=133, Completed, Sponsor: VA Office of Research and Development
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2018 --> Mar 2019 Active, not recruiting --> Completed
- | bupropion sustained-release / Generic mfg.
Trial initiation date: Smoking Cessation Interventions for People Living With HIV in Nairobi, Kenya (clinicaltrials.gov) - Oct 11, 2018
P3, N=300, Not yet recruiting, Sponsor: University of Maryland
Active, not recruiting --> Completed Initiation date: Sep 2018 --> Jan 2019
- | bupropion sustained-release / Generic mfg.
Enrollment closed: Mobile Health Technology to Enhance Abstinence in Smokers With Schizophrenia (clinicaltrials.gov) - Oct 11, 2018
P4, N=35, Active, not recruiting, Sponsor: Duke University
Initiation date: Sep 2018 --> Jan 2019 Recruiting --> Active, not recruiting
- | bupropion sustained-release / Generic mfg.
Trial completion date, Trial primary completion date: Smoking Cessation for People Living With HIV/AIDS (clinicaltrials.gov) - Oct 4, 2018
P=N/A, N=400, Recruiting, Sponsor: Wayne State University
Recruiting --> Active, not recruiting Trial completion date: Jun 2019 --> Dec 2019 | Trial primary completion date: Jun 2019 --> Dec 2019
- | bupropion sustained-release / Generic mfg.
Trial completion, Phase classification, Enrollment change: Combined Pharmaco/Behavior Therapy in Adolescent Smokers (clinicaltrials.gov) - Oct 3, 2018
P2, N=134, Completed, Sponsor: Medical University of South Carolina
Trial completion date: Jun 2019 --> Dec 2019 | Trial primary completion date: Jun 2019 --> Dec 2019 Recruiting --> Completed | Phase classification: PN/A --> P2 | N=216 --> 134
- | bupropion sustained-release / Generic mfg.
Journal: Step Care treatment for smoking cessation. (Pubmed Central) - Jul 18, 2018
Recruiting --> Completed | Phase classification: PN/A --> P2 | N=216 --> 134 For smokers not achieving tobacco abstinence 6 months after randomization with Step 1, the intensity of the intervention increased to four counseling sessions, bupropion sustained-release, nine telephone calls and three mailings (Step 2)...No abstract available
- | bupropion sustained-release / Generic mfg., fluoxetine / Generic mfg.
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Bupropion for Depression in ESRD Patients on Hemodialysis (clinicaltrials.gov) - Jul 17, 2018
P4, N=1, Terminated, Sponsor: University of Arkansas
For smokers not achieving tobacco abstinence 6 months after randomization with Step 1, the intensity of the intervention increased to four counseling sessions, bupropion sustained-release, nine telephone calls and three mailings (Step 2)...No abstract available N=40 --> 1 | Trial completion date: Dec 2018 --> Mar 2018 | Recruiting --> Terminated | Trial primary completion date: Sep 2018 --> Mar 2018; Study stopped due to difficulty recruiting
- | Chantix (varenicline) / Pfizer
Phase classification: Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy (clinicaltrials.gov) - Jul 5, 2018
P1, N=60, Recruiting, Sponsor: Wake Forest University Health Sciences
N=40 --> 1 | Trial completion date: Dec 2018 --> Mar 2018 | Recruiting --> Terminated | Trial primary completion date: Sep 2018 --> Mar 2018; Study stopped due to difficulty recruiting Phase classification: P=N/A --> P1
- | bupropion sustained-release / Generic mfg.
Trial completion: Effect of Bupropion on Seizure Threshold in Depressed Patients (clinicaltrials.gov) - Jun 19, 2018
P4, N=10, Completed, Sponsor: Duke University
Phase classification: P=N/A --> P1 Recruiting --> Completed
- | aripiprazole / Generic mfg., bupropion sustained-release / Generic mfg.
Trial completion: VAST-D: VA Augmentation and Switching Treatments for Improving Depression Outcomes (clinicaltrials.gov) - Jun 3, 2018
P3, N=1522, Completed, Sponsor: VA Office of Research and Development
Recruiting --> Completed Active, not recruiting --> Completed
- | bupropion sustained-release / Generic mfg.
Trial completion date, Trial primary completion date: Smoking Cessation for People Living With HIV/AIDS (clinicaltrials.gov) - Apr 6, 2018
P=N/A, N=400, Recruiting, Sponsor: Wayne State University
Active, not recruiting --> Completed Trial completion date: Dec 2018 --> Jun 2019 | Trial primary completion date: Dec 2018 --> Jun 2019
- | Chantix (varenicline) / Pfizer
Trial completion date, Trial primary completion date: Web-based Smoking Cessation Program for Tribal College Students (clinicaltrials.gov) - Apr 4, 2018
P3, N=300, Recruiting, Sponsor: Won Choi, PhD, MPH
Trial completion date: Dec 2018 --> Jun 2019 | Trial primary completion date: Dec 2018 --> Jun 2019 Trial completion date: Mar 2018 --> Mar 2019 | Trial primary completion date: Feb 2018 --> Jun 2018
- |||| Auvelity (bupropion/dextromethorphan) / Axsome Therap
Enrollment open: AXS-05 Phase II Trial on Smoking Behavior (clinicaltrials.gov) - Apr 2, 2018
P2, N=60, Recruiting, Sponsor: James Davis
Trial completion date: Mar 2018 --> Mar 2019 | Trial primary completion date: Feb 2018 --> Jun 2018 Not yet recruiting --> Recruiting
- ||||| Auvelity (bupropion/dextromethorphan) / Axsome Therap
New P2 trial: AXS-05 Phase II Trial on Smoking Behavior (clinicaltrials.gov) - Mar 21, 2018
P2, N=60, Not yet recruiting, Sponsor: James Davis
- | bupropion sustained-release / Generic mfg.
Phase classification: Abstinence Reinforcement Therapy (ART) for Homeless Veteran Smokers (clinicaltrials.gov) - Mar 13, 2018
P4, N=165, Active, not recruiting, Sponsor: VA Office of Research and Development
Not yet recruiting --> Recruiting Phase classification: P=N/A --> P4
- | bupropion sustained-release / Generic mfg.
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: CPT and Smoking Cessation (clinicaltrials.gov) - Mar 9, 2018
P2/3, N=69, Completed, Sponsor: VA Office of Research and Development
Phase classification: P=N/A --> P4 Active, not recruiting --> Completed | N=50 --> 69 | Trial completion date: Apr 2018 --> Jul 2017 | Trial primary completion date: Apr 2018 --> Jul 2017
- | bupropion sustained-release / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date: Smoking Treatment and Exercise Program for Underserved Populations (STEP UP) (clinicaltrials.gov) - Mar 9, 2018
P=N/A, N=5, Completed, Sponsor: Duke University
Active, not recruiting --> Completed | N=50 --> 69 | Trial completion date: Apr 2018 --> Jul 2017 | Trial primary completion date: Apr 2018 --> Jul 2017 Active, not recruiting --> Completed | Trial completion date: Jan 2018 --> Jul 2017 | Trial primary completion date: Jan 2018 --> Jul 2017
- ||||| Auvelity (bupropion/dextromethorphan) / Axsome Therap
New P2 trial: AXS-05 Phase II Trial on Smoking Behavior (clinicaltrials.gov) - Mar 1, 2018
P2, N=60, Not yet recruiting, Sponsor: James M. Davis, MD
- | Trial completion date, Trial primary completion date: Evaluation of CYP450 Activities in Diabetic Patients vs. Non-diabetic Subjects (clinicaltrials.gov) - Feb 19, 2018
P4, N=126, Recruiting, Sponsor: Centre hospitalier de l'Universit
Active, not recruiting --> Completed | Trial completion date: Jan 2018 --> Jul 2017 | Trial primary completion date: Jan 2018 --> Jul 2017 Trial primary completion date: Jan 2018 --> Jan 2019 | Trial completion date: Oct 2018 --> Oct 2019
- | bupropion sustained-release / Generic mfg.
Trial primary completion date: Bupropion for Smoking Cessation During Pregnancy (clinicaltrials.gov) - Feb 13, 2018
P4, N=65, Completed, Sponsor: The University of Texas Medical Branch, Galveston
Trial primary completion date: Jan 2018 --> Jan 2019 | Trial completion date: Oct 2018 --> Oct 2019 Trial primary completion date: Jul 2016 --> Dec 2016
- | Chantix (varenicline) / Pfizer
Trial completion, Trial primary completion date: The Effect of Varenicline (Chantix) and Bupropion (Zyban) on Smoking Lapse Behavior (clinicaltrials.gov) - Feb 8, 2018
P2, N=62, Completed, Sponsor: Yale University
Trial primary completion date: Jul 2016 --> Dec 2016 Active, not recruiting --> Completed | Trial primary completion date: Jul 2016 --> Oct 2016
- | Chantix (varenicline) / Pfizer
Biomarker, Trial primary completion date: Pharmacogenetics, Emotional Reactivity and Smoking (clinicaltrials.gov) - Feb 2, 2018
P2/3, N=646, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed | Trial primary completion date: Jul 2016 --> Oct 2016 Trial primary completion date: Dec 2018 --> Dec 2019